Story perspectives
$40 Million Plan Aims for Rett Syndrome Cures by 2028
10/1/2025
28 4
1 of 1
Story summary
- Rett Syndrome Research Trust (RSRT) launches a $40 million Roadmap to Cures to bring three genetic medicines into Rett trials by 2028.
- Rett syndrome is a rare genetic disorder caused by MECP2 mutations, mainly affecting girls, onset by 12–18 months.
- RSRT has raised nearly $110 million since inception, with Monica Coenraads as CEO and David Backer as Strategic Advisor.
